Supernus Pharmaceuticals Inc  

(Public, NASDAQ:SUPN)   Watch this stock  
Find more results for William M. Vaughn, III.�
-0.04 (-0.20%)
Sep 4 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 18.96 - 20.45
52 week 7.31 - 23.30
Open 19.52
Vol / Avg. 691,121.00/869,335.00
Mkt cap 952.45M
P/E 28.35
Div/yield     -
EPS 0.69
Shares 48.45M
Beta 0.98
Inst. own 92%
Nov 9, 2015
Q3 2015 Supernus Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 9, 2015
Supernus Pharmaceuticals Inc at FBR Healthcare Conference Add to calendar
Aug 5, 2015
Q2 2015 Supernus Pharmaceuticals Inc Earnings Call - Webcast
Aug 4, 2015
Q2 2015 Supernus Pharmaceuticals Inc Earnings Release
Jun 17, 2015
Supernus Pharmaceuticals Inc Investor Day
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 5.72% 16.28%
Operating margin 8.09% 17.73%
EBITD margin - 20.61%
Return on average assets 5.47% 15.99%
Return on average equity 8.17% 37.92%
Employees 309 -
CDP Score - -


1550 East Gude Drive
United States - Map
+1-301-8382500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR, Trokendi XR, SPN-810, SPN-812 and SPN-809.

Officers and directors

M. James Barrett Ph.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Jack A. Khattar President, Chief Executive Officer, Secretary, Director
Age: 53
Bio & Compensation  - Reuters
Gregory S. Patrick Chief Financial Officer, Vice President
Age: 58
Bio & Compensation  - Reuters
Stefan K.F. Schwabe M.D., Ph.D. Executive Vice-President - Research & Development, Chief Medical Officer
Age: 63
Bio & Compensation  - Reuters
Padmanabh P. Bhatt Ph.D., Senior Vice President- Intellectual Property, Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
Victor Vaughn Senior Vice President - Sales
Age: 57
Bio & Compensation  - Reuters
Georges Gemayel Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
Frederick M. Hudson CPA Independent Director
Age: 69
Bio & Compensation  - Reuters
Charles W. Newhall III Independent Director
Age: 70
Bio & Compensation  - Reuters
William A. Nuerge Independent Director
Age: 62
Bio & Compensation  - Reuters